Andreas Syngros Hospital Of Venereal And Dermatological Diseases
- Address
- lock Available on a paid plan
Dermatology and Venereology Research
At Andreas Syngros Hospital Of Venereal And Dermatological Diseases in Athens, the clinical trial program is strongly centered on skin and connective tissue diseases, with a focus on improving care for chronic inflammatory and immune-mediated conditions. The studies are designed to test new treatments and better understand how to control symptoms, reduce flare-ups, and improve long-term outcomes.
- Atopic dermatitis research evaluating new options for controlling inflammation, itch, and skin damage
- Hidradenitis suppurativa trials testing therapies aimed at reducing disease activity and improving daily quality of life
- Alopecia areata studies focused on restoring hair growth and assessing treatment effectiveness
This work reflects the department’s active role in advancing practical treatment choices for common and often burdensome dermatologic conditions.
Immune-Mediated Skin Disease Studies
A major part of the site’s research portfolio addresses immune system diseases that affect the skin, including conditions where immune activity drives persistent inflammation or visible skin changes. These trials aim to evaluate whether newer therapies can provide better symptom control and more durable responses than current care.
- Active cutaneous lupus erythematosus and systemic lupus erythematosus with skin involvement
- Moderate to severe atopic dermatitis in adolescents and adults
- Hidradenitis suppurativa in patients who need improved immune-targeted treatment options
The research at this hospital highlights a strong interest in therapies that may improve both disease control and patient comfort in long-standing inflammatory skin disorders.
Neoplasm-Focused Clinical Trials
The site also contributes to neoplasm research, with studies involving skin cancer and efforts to improve outcomes after surgery. These trials are intended to assess whether additional treatment can help lower the chance of disease returning and support better cancer control.
- Resectable high-risk locally advanced cutaneous squamous cell carcinoma
- Adjuvant therapy research for reducing recurrence after surgical treatment
- Evaluation of treatment effectiveness in patients with aggressive skin cancer
This area adds an important oncology dimension to the broader dermatology research program at the Andreas Syngros Hospital Of Venereal And Dermatological Diseases.
Bacterial Infections and Mycoses Research
The site’s therapeutic scope also includes bacterial infections and mycoses, reflecting its broader expertise in dermatologic conditions that can overlap with infection-related skin problems. While the main trial activity is concentrated in inflammatory disease, this area remains part of the hospital’s clinical research profile and supports ongoing work on diagnosis and treatment improvement.
- Skin-related infectious disease management
- Improving clinical assessment for conditions that may resemble or coexist with infection
- Supportive research within the dermatology-venereology setting
Together, these studies show a broad dermatologic research environment with emphasis on better recognition, treatment, and long-term care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 68 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 68 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Andreas Syngros Hospital Of Venereal And Dermatological Diseases
lock Showing 1 of 56 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB) | Rheacell GmbH & Co. KG | Phase III | Not Yet Recruiting | Jun 2023 | Jul 2026 |
IMP list
lock Showing 1 of 68 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 4 | Unknown | 2022-11-10 | 2024-10-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.